SYRE vs TECH · $7.60B cap vs P/E 65, rev $1.22B
Spyre Therapeutics Inc. (SYRE) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported SYRE revenue for 2024-12-31 was $0. Net income was -$208.0M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. SYRE currently screens at market cap $7.60B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
SYRE currently screens at market cap $7.60B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the SYRE and TECH stock pages for the full models.
Not investment advice.